Aldesleukin
GET
/api/v1/drug/aldesleukinMechanism of action
Sourced from openFDAMechanism-of-action classes: Interferon Inducers; Interleukin 2 Receptor Agonists.
Interleukin 2 Receptor
Indications
Sourced from openFDA- Take 15 minutes before meals
Dosage & administration
Sourced from openFDADIRECTIONS Take 15 minutes before meals. Adults and children 12 years and older 20 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children between 12 years and 6 years of age 10 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children under 6 years 5 drops twice a day in a glass of water.
Warnings & precautions
Sourced from openFDAStop use and ask doctor if symptoms worsen or persist more than 5 days
Approval history
Sourced from openFDA- May 5, 1992BLABLA103293Chiron
FAERS reports
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
1,205 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
- 1Pyrexia14712%
- 2Hypotension1109.1%
- 3Off Label Use836.9%
- 4Diarrhoea826.8%
- 5Thrombocytopenia826.8%
- 6Vomiting715.9%
- 7Nausea695.7%
- 8Fatigue665.5%
- 9Dyspnoea655.4%
- 10Pain615.1%
- 11Chills605.0%
- 12Drug Ineffective544.5%
- 13Hypoxia534.4%
- 14Disease Progression524.3%
- 15Febrile Neutropenia504.1%
Clinical trials
The 10 most recently updated of 527 ClinicalTrials.gov registrations naming Aldesleukin as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.
- E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated CancersRecruiting · Phase 2 · Interventional · 20 enrolled · Christian HinrichsNCT05686226updated 2026-06-12
- KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung CancerRecruiting · Phase 1 · Interventional · 30 enrolled · Christian HinrichsNCT05483491updated 2026-06-12
- Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruiting · Phase 1 · Interventional · 86 enrolled · National Cancer Institute (NCI)NCT06904066updated 2026-06-12
- E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated CancersRecruiting · Phase 1 · Phase 2 · Interventional · 15 enrolled · Christian HinrichsNCT05639972updated 2026-06-12
- Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerRecruiting · Phase 2 · Interventional · 332 enrolled · National Cancer Institute (NCI)NCT01174121updated 2026-06-11
- A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabRecruiting · Phase 2 · Interventional · 53 enrolled · National Cancer Institute (NCI)NCT02621021updated 2026-06-08
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerRecruiting · Phase 2 · Interventional · 85 enrolled · National Cancer Institute (NCI)NCT02133196updated 2026-06-08
- CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild TypeWithdrawn · Phase 1 · Phase 2 · Interventional · 0 enrolled · Celularity IncorporatedNCT05218408updated 2026-06-08
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersActive not recruiting · Phase 2 · Interventional · 20 enrolled · Udai KammulaNCT03935893updated 2026-06-01
- Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract CancersActive not recruiting · Phase 2 · Interventional · 4 enrolled · Udai KammulaNCT03801083updated 2026-06-01
Frequently asked questions
- How does Aldesleukin work?
- Mechanism-of-action classes: Interferon Inducers; Interleukin 2 Receptor Agonists.
- What is Aldesleukin used for?
- According to FDA labeling, Aldesleukin carries indications including: Take 15 minutes before meals. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
- What class of drug is Aldesleukin?
- Aldesleukin is classified as Interleukins, Lymphocyte Growth Factor, Interferon Inducers, Interleukin 2 Receptor Agonists, Cardiac Rhythm Alteration, Decreased Ventilatory Gas Flow, Increased Cytokine Activity, Increased Cytokine Production, Increased Lymphocyte Activation, Increased Lymphocyte Cell Production.
- What are the brand names for Aldesleukin?
- Aldesleukin is marketed under brand names including Proleukin.
Note. Data for
aldesleukin is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.